Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults

Vaccine

Volumn 27, Issue 49, 2009, Pages 6918-6925

  Leroux Roels, Isabel ^a   Van der Wielen, Marie ^b   Kafeja, Froukje ^b   Vandermeulen, Corinne ^c   Lazarus, Rajeka ^d   Snape, Matthew D ^d   John, Tessa ^d   Carre, Christophe ^e   Nougarede, Nolwenn ^e   Pepin, Stephanie ^e   Leroux Roels, Geert ^a   Hoppenbrouwers, Karel ^c   Pollard, Andrew J ^d   Van Damme, Pierre ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e SANOFI PASTEUR   (France)

Author keywords

Adjuvanted vaccine; H5N1; Influenza vaccine

Indexed keywords

ALUMINUM HYDROXIDE; GAMMA INTERFERON; HEMAGGLUTININ; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INTERLEUKIN 13; INTERLEUKIN 5; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYTOKINE RELEASE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECCHYMOSIS; FATIGUE; FEMALE; GROUPS BY AGE; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALAISE; MALE; MYALGIA; NAUSEA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SORE THROAT; TH1 CELL; TH2 CELL; VIRION;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ALUMINUM HYDROXIDE; ANTIBODIES, VIRAL; CYTOKINES; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; TH1 CELLS; TH2 CELLS; YOUNG ADULT;

EID: 70350570578     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.110     Document Type: Article

References (29)

1. World Health Organization. New influenza A (H1N1) virus: global epidemiological situation, June 2009. Wkly Epidemiol Rec 84 (2009) 249-260
2. World Health Organization. Cumulative number of confirmed cases of avian influenza A/(H5N1) reported to WHO. Available at: http://www.who.int/csr/disease/avian_influenza/country/cases_table_2009_08_11/en/index.html. Accessed 24 August 2009.
3. Ungchusak K., Auewarakul P., Dowell S.F., Kitphati R., Auwanit W., Puthavathana P., et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 352 (2005) 333-340
4. Poland G. Vaccines against avian influenza-a race against time. N Engl J Med 354 (2006) 1411-1413
5. Li K.S., Guan Y., Wang J., Smith G.J., Xu K.M., Duan L., et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430 (2004) 209-213
6. World Health Organization. Responding to the avian influenza pandemic threat: recommended strategic actions. WHO/CDS/CSR/GIP; 2005. Available at: http://www.who.int/csr/resources/publications/influenza/WHO_CDS_CSR_GIP_05_8-EN.pdf. Accessed 24 August 2009.
7. European Centre for Disease Prevention and Control. Pandemic influenza preparedness in the EU/EEA: status report as of Autumn 2007. Technical report. Stockholm; 2007. Available at: http://ecdc.europa.eu/en/Health_Topics/Pandemic_Influenza/pdf/Pandemic_influenza_preparedness_intheEU-EEA.pdf. Accessed 24 August 2009.
8. Jennings L.C., Monto A.S., Chan P.K., Szucs T.D., and Nicholson K.G. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 8 (2008) 650-658
9. Nicolson C., Major D., Wood J.M., and Robertson J.S. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 23 (2005) 2943-2952
10. Hoffmann E., Krauss S., Perez D., Webby R., and Webster R.G. Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 20 (2002) 3165-3170
11. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion Influenza A (H5N1) vaccine. N Engl J Med 354 (2006) 1343-1351
12. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 (2006) 1657-1664
13. Leroux-Roels I., Borkowski A., Vanwolleghem T., Dramé M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomized controlled trial. Lancet 370 (2007) 580-589
14. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomized controlled trial. Lancet 368 (2006) 991-997
15. Levie K., Leroux-Roels I., Hoppenbrouwers K., Kervyn A.D., Vandermeulen C., Forgus S., et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 198 (2008) 642-649
16. Subbarao K., and Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol 7 (2007) 267-278
17. Chotpitayasunondh T., Thisyakorn U., Pancharoen C., Pepin S., and Nougarede N. Safety, humoral and cell mediated immune responses to two formulations of an inactivated, split-virion influenza A/H5N1 vaccine in children. PLoS ONE 3 (2008) e4028
18. Vajo Z., Kosa L., Szilvasy I., Pauliny Z., Bartha K., Visontay I., et al. Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children. Pediatr Infect Dis J 27 (2008) 1052-1056
19. Nolan T., Richmond P.C., Formica N.T., Höschler K., Skeljo M.V., Stoney T., et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 26 (2008) 6383-6391
20. Banzhoff A., Gasparini R., Laghi-Pasini F., Staniscia T., Durando P., Montomoli E., et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 4 (2009) e4384
21. Stephenson I., Wood J.M., Nicholson K.G., Charlett A., and Zambon M.C. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 103 (2004) 91-95
22. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., Fukuda K., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37 (1999) 937-943
23. European Committee for Proprietary Medicinal Products. Note for guidance on harmonization of requirements for influenza vaccines; 1997. CPMP/BWP/214/96.
24. European Medicines Agency Committee for Medicinal Products for Human Use. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorization application. EMEA/CPMP/VEG/4717/03-Rev.1; 2008. Available at: http://www.emea.europa.eu/pdfs/human/vwp/471703en.pdf. Accessed 24 August 2009.
25. Epstein S.L. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 193 (2006) 49-53
26. Stephenson I., Nicholson K.G., Glück R., Mischler R., Newman R.W., Palache A.M., et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 362 (2003) 1959-1966
27. Roti M., Yang J., Berger D., Huston L., James E.A., and Kwok W.W. Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus. J Immunol 180 (2008) 1758-1768
28. Gioia C., Castilletti C., Tempestilli M., Piacentini P., Bordi L., Chiappini R., et al. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis 14 (2008) 121-128
29. Thomas P.G., Keating R., Hulse-Post D.J., and Doherty P.C. Cell-mediated protection in influenza infection. Emerg Infect Dis 12 (2006) 48-54